Skip to main content

Volume 6 Supplement 6

Beyond the Genome 2012

Interrogating of cancer genomes: towards more profile-based therapeutics

Although death rates due to common diseases such as heart disease, stroke and infectious diseases have declined over the last half-century, there has been only a small change in cancer mortality rates. The availability of the draft human genome sequence and a number of technological advances now provide us with the opportunity to explore the genomic landscape of cancer in an unprecedented way. Here, we will describe the application of multiple genomic technologies toward the interrogation of a number of cancer genomes, in order to discover molecular determinants of cancer that might be associated with clinical outcome and those that might be candidates for targeted therapy. It is our hope that these data would one day be translated into clinical practice to improve therapeutic decision-making for more knowledge-based clinical management.

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Carpten, J.D. Interrogating of cancer genomes: towards more profile-based therapeutics. BMC Proc 6 (Suppl 6), O16 (2012).

Download citation

  • Published:

  • DOI:


  • Public Health
  • Death Rate
  • Clinical Practice
  • Heart Disease
  • Clinical Outcome